Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, FTD/TPI, with Ramucirumab Murine Version DC101 in a Mouse Syngeneic Cancer Transplantation Model

Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, FTD/TPI, with Ramucirumab Murine Version DC101 in a Mouse Syngeneic Cancer Transplantation Model

Trifluridine/tipiracil (FTD/TPI) (a.k.a. TAS-102) is a combination drug for metastatic colorectal cancer (CRC) and severely pretreated metastatic gastric/gastroesophageal junction (GEJ) cancers, comprising FTD, a thymidine-based antineoplastic nucleoside analog, and TPI, which enhances FTD bioavaila...

Full description

Bibliographic Details
Main Authors: Kenta Tsunekuni, Hisato Kawakami, Kazuaki Matsuoka, Hideki Nagase, Seiichiro Mitani, Kazuhiko Nakagawa
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Journal of Clinical Medicine
Subjects:
trifluridine/tipiracil
colorectal cancer
combination drug therapy
ramucirumab
mouse syngeneic transplantation
Online Access:https://www.mdpi.com/2077-0383/9/12/4050

Internet

https://www.mdpi.com/2077-0383/9/12/4050

Similar Items